Dyadic Q3 net loss $1.8M; SAHPRA clears Phase 1 COVID-19 vaccine trial

DYADIC INTERNATIONAL INC

Net loss $1.809M ($0.06/share); revenue $0.88M vs $0.693M YoY increase.
Cash and investments $14.2M; expects to fund operations into 2024.
SAHPRA approved Phase 1 trial for DYAI-100 COVID-19 RBD booster; enrollment planned later 2022.
R&D expenses fell to $0.744M from $1.902M YoY as pre-clinical activities wound down.
9x improvement in Nivolumab expression to 22.3 g/L; livestock antigen titers up to 10 g/L.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DYADIC INTERNATIONAL INC reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Dyadic International, Inc. ("Dyadic”) issued a press release announcing its results for the quarter ended September 30, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-22-026890

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.